Payload Information

General Information of This Payload

Payload ID	PAY0GSHBE
Name	Auristatin W derivative
Synonyms	Auristatin W derivative Click to Show/Hide
Target(s)	Microtubule (MT)	Target Info

Each Antibody-drug Conjugate Related to This Payload

Full Information of The Activity Data of The ADC(s) Related to This Payload

Aprutumab ixadotin [Phase 1]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Patients Enrolled	Advanced solid tumors from cancer indications known to be FGFR2-positive, which were refractory to any standard therapy or had no standard therapy available, patients were required to have measurable disease, Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1, an expected lifespan of at least 12 weeks.
Administration Dosage	The starting dose was 0.1 mg/kg body weight, with doses increased in two-fold increments up to 0.80 mg/kg, after which the dose was escalated in 0.50 mg/kg increments, intravenously on day 1 of every 21-day cycle.
*Related Clinical Trial*
NCT Number	NCT02368951	Phase Status	Phase 1
Clinical Description	An open-label,phase 1, dose-escalation trial to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetic, and pharmacodynamics of the anti-FGFR2 antibody drug conjugate BAY1187982 in subjects with advanced solid tumors known to express FGFR2.
Primary Endpoint	Primary endpoints included safety, tolerability, and The MTD was determined to be 0.20 mg/kg.
Other Endpoint	Secondary endpoints were pharmacokinetic evaluation and tumor response to aprutumab ixadotin.

References

Ref 1	First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer. Target Oncol. 2019 Oct;14(5):591-601.